Home › MediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence
 

Keywords :   


MediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence

2014-09-08 02:29:34| Biotech - Topix.net

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that Columbia University and the New York State Psychiatric Institute was awarded new grant funding from the National Institute on Drug Abuse to continue clinical research on MN-166 in opioid dependence. The new grant will support the completion of a Phase 2a clinical trial of MN-166 in opioid dependence, for which positive interim results were previously reported by MediciNova on August 18, 2014.

Tags: grant dependence announces opioid

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Tropical Storm Lane Graphics
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Forecast Discussion Number 4
02.11Subtropical Storm Patty Wind Speed Probabilities Number 2
02.11Summary for Tropical Storm Lane (EP3/EP132024)
02.11Subtropical Storm Patty Public Advisory Number 2
02.11Subtropical Storm Patty Forecast Advisory Number 2
02.11Subtropical Storm Patty Update Statement
More »